Rosiglitazone storm poised for touchdown

Links shared publicly online about this topic.

1,035
total visits

Rosiglitazone storm poised for touchdown

UPDATED // The FDA documents, which provide a glimpse of what the agency's presentations will look like next week, are largely critical of rosiglitazone's safety record and of the ethics of the ongoing TIDE trial. In sharp contrast, GlaxoSmithKline's documents reiterate the need for a randomized controlled trial to resolve uncertainties and conclude that by and large the data support

View full resource at theheart.org

Tags: Diabetes Type 2 Medication, Diabetes Medication, FDA, Avandia, Avandamet, Avandaryl, GlaxoSmithKline